Influenza in Medical Technology

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone

ROCKVILLE, Md., Aug. 5 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today it has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus under current good-manufacturing practices (cGMP) at its new vaccine manufactu...

AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine

RESEARCH TRIANGLE PARK, N.C., July 17 /PRNewswire/ -- AlphaVax, Inc. announced today that it has completed process development and preclinical immunogenicity studies of its H1N1 (swine) influenza vaccine and will manufacture clinical trial material by the end of the month. This vaccin...

Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS

- Phase II clinical trial investigating the effectiveness of Intercell's Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine started today in the U.S. - The study is fully funded by HHS - this is the second study conducted under a 5 year USD 128 m ...

Senesco Announces H1N1 Influenza Survival Test Results in Mice

NEW BRUNSWICK, N.J., May 26 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT ) today reported results of H1N1 mouse influenza survival studies that were conducted in Dr. William Scheld's lab at the University of Virginia School of Medic...

Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial

Completion of enrollment keeps Company on track to report primary study results in third quarter of this year ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today that enrollment has been completed in the second Phase II clinical trial of its trival...

Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma

LACHEN, Switzerland, May 1 /PRNewswire/ -- - Company Working With Authorities to Ensure Adequate Supply of Virally Inactivated Plasma Derivatives The impending influenza pandemic will have implications for global stocks of life-saving blood and blood products, warns Swiss-based g...

Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development

BOXMEER, Netherlands, March 13 /PRNewswire-FirstCall/ -- Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP ), today announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new...

Children's Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia

CINCINNATI, Feb. 24 /PRNewswire-USNewswire/ -- Cincinnati Children's Hospital Medical Center has received a $6.7 million grant from the Bill & Melinda Gates Foundation to help prevent flu in pregnant women and their infants in rural areas around the world. Most childhood deaths occur in...

Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections

BIRMINGHAM, Ala., Feb. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented by the study's Principal Investigator, Dr. Michael G. Ison, Assi...

Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate

Results support that Novavax's Recombinant Technology May Offer a Powerful, New Approach for Development of the Next Generation of Influenza Vaccines with Broad Protection Against Multiple Strains ROCKVILLE, Md., Feb. 19 /PRNewswire-FirstCall/ -- NOVAVAX (Nasdaq: NVAX ) announced today favo...

Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference

VLP Vaccine - Coupled with Innovative Manufacturing - Has Potential to Address Gaps in Global Pandemic Preparedness ROCKVILLE, Md., Feb. 17 /PRNewswire-FirstCall/ -- At the 5th World Health Organization Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials, Novavax...

USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)

VIENNA, Austria, Dec. 11 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced the execution of a contract modification with the U.S. Department of Health and Human Services (HHS). The agreement commits additional funding of USD 12.5 m for Intercell's Pandemic Influenza program. Interc...

Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate

Favorable immunogenicity results for seasonal vaccine program follows positive results from its pandemic influenza vaccine Phase IIa trial in July 2008; plans to initiate a study of the seasonal vaccine in the elderly in 2009 ROCKVILLE, Md., Dec. 11 /PRNewswire-FirstCall/ -- Novavax, Inc...

Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans

LAS VEGAS, Dec. 11 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced that the company's Vaxfectin (R)-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody response...

Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated

American Lung Association's 2008 Faces of Influenza survey underscores that mothers need to get families immunized against influenza; Mother and Gold Medalist Kristi Yamaguchi joins initiative WASHINGTON, Nov. 18 /PRNewswire/ -- While 78 percent of mothers in the United States consider i...

Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program

VLP Vaccine - Coupled with Innovative Manufacturing - Has Potential to Address Gaps in Global Pandemic Preparedness ROCKVILLE, Md., Aug. 26 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today favorable results from the second stage of the Phase I/IIa human cl...

Inverness Medical Innovations Receives USDA Licensure of the BinaxNOW(R) Avian Influenza Virus Type A Antigen Test Kit

WALTHAM, Mass., Aug. 11 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA ), a leading provider of near-patient diagnostics, monitoring and health management solutions, announced today that it has received licensure from the United States Department of Agriculture (USDA...

Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US

SWIFTWATER, Pa. and LYON, France, Aug. 1 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, began shipping influenza vaccine (Fluzone(R), Influenza Virus Vaccine) in the United States for the 2008-2009 season. The first 1.3 million doses of influenza vaccine began s...

BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting

BIRMINGHAM, Ala., July 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced preliminary results of a Phase II study of intravenous (i.v.) peramivir administered via a single dose injection in the outpatient setting for the treatment of seasonal influenza...

Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data

SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced a breakthrough with preliminary clinical trial data demonstrating that DNA vaccines can safely achieve significant immune responses against H5N1 pandemic influenza in humans. DNA vaccines are funda...

Start of Phase I Study for Intranasal Pandemic Influenza Vaccine deltaFLU

VIENNA, Austria, July 8 /PRNewswire/ -- Avir Green Hills Biotechnology starts a clinical phase I study with its intranasal vaccine deltaFLU against pandemic influenza. This novel generation of a live-attenuated vaccine based on the deletion of the NS1 gene has shown superior preclinical data. ...

Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine

BEIJING, June 30 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced the initiation of volunteer enrollment in its Phase II clinical trial for its split pandemic influenza vaccine. The preliminary results from this study are expecte...

Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile

LYON, France and SWIFTWATER, Pa., June 16 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today its commitment to donate 60 million doses of H5N1 vaccine to the World Health Organization (WHO) over 3 years for the establishment of an H5N1 vaccine global...

Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial

ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has completed enrollment in the Phase I/IIa study of its pandemic influenza vaccine including a total of approximately 230 subjects. Favorable interim results from the first phase of the study...

Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate

Results Support Moving Forward with a planned IND Filing for Novavax's Seasonal Influenza Vaccine Candidate ROCKVILLE, Md., April 16 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) said today that it has received positive results from an immunogenicity study in ferre...

Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch

- Dose-Ranging Trial to Further Assess Feasibility of Dose-sparing and Single-Dose Vaccination Against H5N1 Flu - GAITHERSBURG, Md., April 15 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI ) today announced that it has received approval from the Department of Health ...

Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program

ROCKVILLE, Md., Dec. 20 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today favorable interim results from a Phase I/IIa human clinical trial of its non-adjuvanted pandemic influenza virus-like particle (VLP) vaccine candidate. Penny Heaton, MD, Chief Medical Officer and...

Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program

ROCKVILLE, Md., Dec. 17 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today favorable results from preclinical studies of its recombinant trivalent seasonal influenza virus-like particle (VLP) vaccine. The trivalent seasonal influenza vaccine is the second of two influenza...

GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution

* Collaboration aimed at enabling vaccine production facility commissioning in half the time of a traditional egg-based facility. * Once established, such a vaccine facility could allow manufacturing of pandemic flu vaccine to commence within 12 weeks of the strain isolation CHALFONT...

Childhood Influenza Immunization Coalition Encourages Vaccination Throughout the Influenza Season

Centers for Disease Control and Prevention (CDC), Families Fighting Flu Declare November 27 National Children's Flu Vaccination Day BETHESDA, Md., Nov. 27 /PRNewswire/ -- To raise awareness of the need to vaccinate more infants, children and adolescents against influenza, the Centers for ...

Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials

BEIJING, Nov. 19 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced an update on the clinical trials for its pandemic influenza vaccines. Sinovac received approval in April 2007 from the China State Food and Drug ...

Actress and Mother Jennifer Garner Kicks Off American Lung Association's Faces of Influenza Awareness Campaign, Encouraging Families to Get Vaccinated Against Influenza

NEW YORK, Nov. 12 /PRNewswire-USNewswire/ -- Actress Jennifer Garner joined leading medical officials at a press conference today to kick off the American Lung Association's national Faces of Influenza public awareness campaign, urging Americans to get their annual influenza vaccination. The p...

Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine

SWIFTWATER, Pa., and LYON, France, Nov. 7 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has initiated Phase II testing of its cell culture-based seasonal influenza vaccine in the U.S. The initiation of Phase I was announced on...

AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial

RESEARCH TRIANGLE PARK, N.C., Oct. 31 /PRNewswire/ -- AlphaVax, Inc. announced today that it has concluded a phase 1 clinical trial in 216 volunteers of an influenza vaccine based on its proprietary replicon vector platform. This study was designed to further assess the properties of this uniq...

Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination

Garner to Kick-Off Faces of Influenza Campaign in New York City Monday, November 12 NEW YORK, Oct. 18 /PRNewswire/ -- Actress Jennifer Garner joins the American Lung Association in a new role as national spokesperson for the Association's Faces of Influenza educati...

Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant

LYON, France, Oct. 9 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced that data from a study in mice demonstrated the potential of its patented Vaxfectin(TM) adjuvant to be used as a dose-sparing agent with a protein-based H5N1 pandemic influenza vaccine currently ...

Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies

CARLSBAD, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that its wholly owned subsidiary, Ibis Biosciences, Inc. (Ibis), has been awarded a subcontract of a National Institutes of Health (NIH) grant to aid in influenza surveillance resea...

Seriously Low Vaccination Rates Cause Experts to Call for Increased Immunization Before Influenza Season Peaks

Paradigm Shift Needed to Ensure Americans Seek Vaccination Now Through the Fall and Winter Months WASHINGTON, Sept. 19 /PRNewswire-USNewswire/ -- New data, released today by the Centers for Disease Control and Prevention (CDC), show alarmingly low influenza vaccination rates in both adults a...

Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine

BEIJING, Sept. 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading China-based biopharmaceutical company focusing on human vaccine development, announced today that it has commenced vaccination of volunteers for its Phase II clinical research study of its pandemic influenza H...

Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine

- Trial to Assess Safety and Dose-Sparing Capability of Iomai Adjuvant Patch - GAITHERSBURG, Md., Sept. 6 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI ) today announced that it has begun dosing in a Phase 1/2 study that will assess the safety and d...